Skip to main content

A prospective observational study to evaluate G-CSF usage in patients with solid tumors receiving myelosuppressive chemotherapy in Italian clinical oncology practice

Medical Oncology volume 31, Article number: 797 (2014) Cite this article

Abstract

Febrile neutropenia (FN) is a severe dose-limiting side effect of myelosuppressive chemotherapy in patients with solid tumors. Clinical practice guidelines recommend primary prophylaxis with G-CSF in patients with an overall ≥20 % risk of FN. AIOM Italian guidelines recommend starting G-CSF within 24–72 h after chemotherapy; for daily G-CSF, administration should continue until the absolute neutrophil count (ANC) is 1 × 109/L post-nadir and should not be terminated after ANC increase in the early days of administration. The aim of this study was to assess guideline adherence in oncology practice in Italy. In this multicenter, prospective, observational study, patients were enrolled at the first G-CSF use in any cycle and were followed for two subsequent cycles (or until the end of chemotherapy if less than two additional cycles). Primary objective was to explore G-CSF use in Italian clinical practice; therefore, data were collected on the G-CSF type, timing of administration, and number of doses. 512 eligible patients were enrolled (median age, 62). The most common tumor types were breast (36 %), lung (18 %), and colorectal (13 %). A total of 1,164 G-CSF cycles (daily G-CSF, 718; pegfilgrastim, 446) were observed. Daily G-CSF was administered later than 72 h after chemotherapy in 42 % of cycles, and the median [range] number of doses was four [1, 10]. Pegfilgrastim was administered later than 72 h in 8 % of cycles. G-CSF prophylaxis in Italy is frequently administered in a manner which is not supported by evidence-based guidelines. As this practice may lead to poor outcomes, educational initiatives are recommended.

This is a preview of subscription content, access via your institution.

Access options

Buy single article

Instant access to the full article PDF.

USD 39.95

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Fig. 1
Fig. 2

Notes

  1. Granulokine® is the Italian brand name for Neupogen®.

  2. Granulokine® is the Italian brand name for Neupogen®.

  3. Granulokine® is the Italian brand name for Neupogen®.

References

  1. Kuderer NM, Dale DC, Crawford J, et al. Mortality, morbidity, and cost associated with febrile neutropenia in adult cancer patients. Cancer. 2006;106:2258–66.

    Article  PubMed  Google Scholar 

  2. Pettengell R, Schwenkglenks M, Leonard R, et al. Neutropenia occurrence and predictors of reduced chemotherapy delivery: results from the INC-EU prospective observational European neutropenia study. Support Care Cancer. 2008;16:1299–309.

    Article  PubMed  Google Scholar 

  3. Chirivella I, Bermejo B, Insa A, et al. Optimal delivery of anthracycline-based chemotherapy in the adjuvant setting improves outcome of breast cancer patients. Breast Cancer Res Treat. 2009;114:479–84.

    Article  CAS  PubMed  Google Scholar 

  4. Crawford J, Ozer H, Stoller R, et al. Reduction by granulocyte colony-stimulating factor of fever and neutropenia induced by chemotherapy in patients with small-cell lung cancer. N Engl J Med. 1991;325:164–70.

    Article  CAS  PubMed  Google Scholar 

  5. Vogel CL, Wojtukiewicz MZ, Carroll RR, et al. First and subsequent cycle use of pegfilgrastim prevents febrile neutropenia in patients with breast cancer: a multicenter, double-blind, placebo-controlled phase III study. J Clin Oncol. 2005;23:1178–84.

    Article  CAS  PubMed  Google Scholar 

  6. Kuderer NM, Dale DC, Crawford J, Lyman GH. Impact of primary prophylaxis with granulocyte colony-stimulating factor on febrile neutropenia and mortality in adult cancer patients receiving chemotherapy: a systematic review. J Clin Oncol. 2007;25:3158–67.

    Article  CAS  PubMed  Google Scholar 

  7. Gatzemeier U, Kleisbauer JP, Drings P, et al. Lenograstim as support for ACE chemotherapy of small-cell lung cancer: a phase III, multicenter, randomized study. Am J Clin Oncol. 2000;23:393–400.

    Article  CAS  PubMed  Google Scholar 

  8. Lyman GH, Dale DC, Wolff DA, et al. Acute myeloid leukemia or myelodysplastic syndrome in randomized controlled clinical trials of cancer chemotherapy with granulocyte colony-stimulating factor: a systematic review. J Clin Oncol. 2010;28:2914–24.

    Article  PubMed  Google Scholar 

  9. von Minckwitz G, Kummel S, du Bois A, et al. Pegfilgrastim ± ciprofloxacin for primary prophylaxis with TAC (docetaxel/doxorubicin/cyclophosphamide) chemotherapy for breast cancer. Results from the GEPARTRIO study. Ann Oncol. 2008;19:292–8.

    Article  Google Scholar 

  10. Citron ML, Berry DA, Cirrincione C, et al. Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: first report of Intergroup Trial C9741/Cancer and Leukemia Group B Trial 9741. J Clin Oncol. 2003;21:1431–9.

    Article  CAS  PubMed  Google Scholar 

  11. Pfreundschuh M, Trumper L, Kloess M, et al. Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of young patients with good-prognosis (normal LDH) aggressive lymphomas: results of the NHL-B1 trial of the DSHNHL. Blood. 2004;104:626–33.

    Article  CAS  PubMed  Google Scholar 

  12. Aapro MS, Cameron DA, Pettengell R, et al. EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphomas and solid tumours. Eur J Cancer. 2006;42:2433–53.

    Article  CAS  PubMed  Google Scholar 

  13. Smith TJ, Khatcheressian J, Lyman GH, et al. 2006 update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline. J Clin Oncol. 2006;24:3187–205.

    Article  CAS  PubMed  Google Scholar 

  14. Network NCC. National comprehensive cancer network clinical practice guidelines in oncology: myeloid growth factors. http://www.nccn.org/professionals/physician_gls/PDF/myeloid_growth.pdf 2010; Version 1.2010.

  15. http://www.aiom.it/default.asp. Associazione Italiana di Oncologica Medica.

  16. Crawford J, Caserta C, Roila F. Hematopoietic growth factors: ESMO recommendations for the applications. Ann Oncol. 2009;20(Suppl 4):162–5.

    PubMed  Google Scholar 

  17. Neupogen/Granulokine (Granulokine® is the Italian brand name for Neupogen®) Summary of Product Characteristics. Amgen Ltd.

  18. Lenograstim Summary of Product Characteristics. Chugai Pharma UK Ltd.

  19. Trillet-Lenoir V, Green J, Manegold C, et al. Recombinant granulocyte colony stimulating factor reduces the infectious complications of cytotoxic chemotherapy. Eur J Cancer. 1993;29A:319–24.

    Article  CAS  PubMed  Google Scholar 

  20. Almenar D, Mayans J, Juan O, et al. Pegfilgrastim and daily granulocyte colony-stimulating factor: patterns of use and neutropenia-related outcomes in cancer patients in Spain–results of the LEARN study. Eur J Cancer Care (Engl). 2009;18:280–6.

    Article  CAS  Google Scholar 

  21. Weycker D, Hackett J, Edelsberg JS, et al. Are shorter courses of filgrastim prophylaxis associated with increased risk of hospitalization? Ann Pharmacother. 2006;40:402–7.

    Article  CAS  PubMed  Google Scholar 

  22. Morrison VA, Wong M, Hershman D, et al. Observational study of the prevalence of febrile neutropenia in patients who received filgrastim or pegfilgrastim associated with 3–4 week chemotherapy regimens in community oncology practices. J Manag Care Pharm. 2007;13:337–48.

    PubMed  Google Scholar 

  23. Lyman GH, Dale DC, Crawford J. Incidence and predictors of low dose-intensity in adjuvant breast cancer chemotherapy: a nationwide study of community practices. J Clin Oncol. 2003;21:4524–31.

    Article  PubMed  Google Scholar 

  24. Papaldo P, Lopez M, Marolla P, et al. Impact of five prophylactic filgrastim schedules on hematologic toxicity in early breast cancer patients treated with epirubicin and cyclophosphamide. J Clin Oncol. 2005;23:6908–18.

    Article  CAS  PubMed  Google Scholar 

  25. von Minckwitz G, Schwenkglenks M, Skacel T, et al. Febrile neutropenia and related complications in breast cancer patients receiving pegfilgrastim primary prophylaxis versus current practice neutropaenia management: results from an integrated analysis. Eur J Cancer. 2009;45:608–17.

    Article  Google Scholar 

  26. Johnston E, Crawford J, Blackwell S, et al. Randomized, dose-escalation study of SD/01 compared with daily filgrastim in patients receiving chemotherapy. J Clin Oncol. 2000;18:2522–8.

    CAS  PubMed  Google Scholar 

  27. Yang BB, Kido A, Shibata A. Serum pegfilgrastim concentrations during recovery of absolute neutrophil count in patients with cancer receiving pegfilgrastim after chemotherapy. Pharmacotherapy. 2007;27:1387–93.

    Article  CAS  PubMed  Google Scholar 

  28. Holmes FA, Jones SE, O’Shaughnessy J, et al. Comparable efficacy and safety profiles of once-per-cycle pegfilgrastim and daily injection filgrastim in chemotherapy-induced neutropenia: a multicenter dose-finding study in women with breast cancer. Ann Oncol. 2002;13:903–9.

    Article  CAS  PubMed  Google Scholar 

  29. Holmes FA, O’Shaughnessy JA, Vukelja S, et al. Blinded, randomized, multicenter study to evaluate single administration pegfilgrastim once per cycle versus daily filgrastim as an adjunct to chemotherapy in patients with high-risk stage II or stage III/IV breast cancer. J Clin Oncol. 2002;20:727–31.

    Article  CAS  PubMed  Google Scholar 

  30. Green MD, Koelbl H, Baselga J, et al. A randomized double-blind multicenter phase III study of fixed-dose single-administration pegfilgrastim versus daily filgrastim in patients receiving myelosuppressive chemotherapy. Ann Oncol. 2003;14:29–35.

    Article  CAS  PubMed  Google Scholar 

  31. Neulasta Summary of Product Characteristics. Amgen.

  32. Lyman GH. Guidelines of the National Comprehensive Cancer Network on the use of myeloid growth factors with cancer chemotherapy: a review of the evidence. J Natl Compr Cancer Netw. 2005;3:557–71.

    Google Scholar 

  33. Koumakis G, Vassilomanolakis M, Barbounis V, et al. Optimal timing (preemptive versus supportive) of granulocyte colony-stimulating factor administration following high-dose cyclophosphamide. Oncology. 1999;56:28–35.

    Article  CAS  PubMed  Google Scholar 

  34. Crea F, Giovannetti E, Zinzani PL, Danesi R. Pharmacologic rationale for early G-CSF prophylaxis in cancer patients and role of pharmacogenetics in treatment optimization. Crit Rev Oncol Hematol. 2009;72:21–44.

    Article  PubMed  Google Scholar 

  35. Lyman G, Lalla A, Barron R, Dubois RW. Cost-effectiveness of pegfilgrastim versus 6-day filgrastim primary prophylaxis in patients with non-Hodgkin’s lymphoma receiving CHOP-21 in United States. Curr Med Res Opin. 2009;25:401–11.

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgments

This study was supported by Amgen-Dompé, Milan, Italy. Wanda J. Krall, PhD, a medical writer funded by Amgen (Europe) GmbH, assisted with the drafting of this manuscript. Thanks to Valter Torri for providing some additional statistical analysis.

Conflict of interest

The authors declare no conflict of interest.

Author information

Authors and Affiliations

  1. Oncology Department, Azienda Ospedaliera Treviglio, Treviglio, BG, Italy

    S. Barni

  2. National Cancer Research Centre Istituto Tumori Giovanni Paolo II, Bari, Italy

    V. Lorusso

  3. Oncology Department, Azienda Ospedaliera Sant’Anna, Como, Italy

    M. Giordano

  4. Oncology Department, Ospedale San Paolo, Savona, Italy

    G. Sogno

  5. Oncology Department, Osp SS Trinità, Sora, Italy

    T. Gamucci

  6. Humanitas Cancer Center, Rozzano, Milan, Italy

    A. Santoro

  7. Oncology Department, Istituti Ospitalieri, Cremona, Italy

    R. Passalacqua

  8. Oncology Department, I.N.T. Fondazione G Pascale, Naples, Italy

    V. Iaffaioli

  9. Oncology Department “Oncologia Medica 1”, Fondazione IRCCS “Istituto Nazionale dei Tumori”, Milan, Italy

    N. Zilembo

  10. Oncology Department, Ospedale Villa Scassi, Genoa, Italy

    M. Mencoboni

  11. Oncology Department, Tor Vergata Clinical Center, University of Rome Tor Vergata, Rome, Italy

    M. Roselli

  12. Office of Clinical Epidemiology, Department of Medical Sciences, Azienda ULSS 13, Mirano, VE, Italy

    G. Pappagallo

  13. Oncology Department A, IST, Istituto Nazionale per la Ricerca sul Cancro, IRCCS Azienda Ospedaliera Universitaria San Martino, Genoa, Italy

    P. Pronzato

  14. Ospedale di Treviglio, Treviglio, BG, Italy

    S. Barni

Authors
  1. S. Barni
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. V. Lorusso
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. M. Giordano
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. G. Sogno
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. T. Gamucci
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. A. Santoro
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. R. Passalacqua
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. V. Iaffaioli
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. N. Zilembo
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. M. Mencoboni
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. M. Roselli
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. G. Pappagallo
    View author publications

    You can also search for this author in PubMed Google Scholar

  13. P. Pronzato
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to S. Barni.

Additional information

This study was carried out on behalf of OBSERVE investigators.

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Barni, S., Lorusso, V., Giordano, M. et al. A prospective observational study to evaluate G-CSF usage in patients with solid tumors receiving myelosuppressive chemotherapy in Italian clinical oncology practice. Med Oncol 31, 797 (2014). https://doi.org/10.1007/s12032-013-0797-z

Download citation

  • Received:

  • Accepted:

  • Published:

  • DOI: https://doi.org/10.1007/s12032-013-0797-z

Keywords

  • G-CSF
  • Solid tumors
  • Observational study
  • Oncology practice
  • Italy
  • Guidelines